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Abstract
Background Total hip arthroplasty is a successful treatment for hip osteoarthritis. Primary and secondary implant fixation 
is dependent on implant design and plays an important role in the longevity of an implant. In this study, we assessed the 
self-locking cementless  MasterSL femoral stem.
Materials and methods In this single-centre prospective study, 50 consecutive hips with the indication for total hip arthro-
plasty, who met the inclusion criteria, received the  MasterSL stem from LIMA Corporate. Patients had pre- and post-operative 
clinical and radiological assessment and completed patient-reported outcome measures [Oxford Hip Score (OHS), Harris 
Hip Score (HHS) and Forgotten Joint Score (FJS)] at the 6-week and 6-, 12- and 24-month mark. Post-operative X-rays were 
assessed for osteointegration (Engh Score), alignment and subsidence.
Results After 2 years, aseptic survival was 100%. One hip had to be explanted due to early deep infection and was 
excluded from the study. At 2 years, the patients reported a significant improved HHS and OHS of 95.3 ± 5.8 and 46.1 ± 3.6 
(mean ± standard deviation), respectively, compared to preoperatively. The mean ± standard deviation for the FJS was 
86.4 ± 18.7 with two-thirds of the patients reporting a score above 85. The mean Engh score is 15.1 ± 5.9 (mean ± standard 
deviation) with no patient scoring below 1 which suggests good osteointegration in all femoral stems.
Conclusions The  MasterSL femoral stem performed well in this short-term follow-up study, with high patient satisfaction 
and good signs of osteointegration. Long-term follow-up will be necessary to evaluate longevity.
Level of evidence Level 3, Prospective cohort study.
Trial registration The study was registered on the 30.03.2016 with Australia New Zealand Clinical Trials Registry 
(ACTRN12617000550303).
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Abbreviations
OHS  Oxford hip score
HHS  Harris hip Score
FJS  Forgotten joint score
THA  Total hip arthroplasty
AP  Anterior–posterior
PROM  Patient-reported outcome measures
ROM  Range of motion
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BMI  Body mass index
CoCrMo  Cobalt–chromium–molybdenum
TT  Trabecular titanium
CT  Computed tomography
CTPA  Computed tomography of pulmonary arteries
ASA  American society of anesthesiologist
Introduction
Total hip arthroplasty (THA) has proven to be one of the 
most successful treatments in the field of orthopaedic sur-
gery, even described as the “operation of the century” [1]. 
Over 1 million THAs are performed worldwide [2], and in 
Australia, it is one of the most common elective procedures 
undertaken with a 65% increase since 2003 [3]. THA is 
considered the gold-standard treatment for advanced oste-
oarthritis of the hip; it is highly successful in improving 
patients’ pain, achieving excellent functional results, and 
has a proven track record of long-term survivorship [4]. 
Despite these successes, some THAs need revision, and with 
the rising number of procedures performed, the number of 
revisions also rises. Although the reasons for revision are 
multifactorial, on-going improvements in implant design are 
necessary in order to reduce the burden of such procedures 
on both the patient and the healthcare system [5].
Prosthetic hip implants have evolved over the past half a 
century, and contemporary technologies are driving innova-
tion of improved prosthetic designs. When a new implant is 
introduced into the market, it is important to demonstrate 
that it is safe, reliable and easy for the surgeon to use with 
minimal to no learning curve. The new implant should pro-
duce at least equivalent but preferably superior results in 
terms of survivorship, alignment, complications and patient 
outcomes when compared to current available options. The 
 MasterSL (self-locking) is a redesigned version of the exist-
ing SL femoral stem produced by LIMA Corporate, with 
changes to the anterior–posterior (AP) thickness and stem 
offset, which is proposed to produce a more anatomical 
reconstruction (Fig. 1). The collarless design of the implant 
allows full seating into the prepared canal (self-locking prin-
ciple). The  MasterSL system offers a greater variety of stem 
sizes, in both standard (neck-shaft angle: 131°) and lateral-
ised (neck-shaft angle: 127.5°) offset. The sizing follows a 
linear increase in AP thickness, geometrical increment and 
offset. The proximal portion has a reduced lateral shoulder 
and the distal tip has been laterally rounded, to aid in mini-
mally invasive surgical techniques and minimise cortical 
bone contact. The  MasterSL femoral stem has a porous and 
hydroxyapatite-coated surface in the proximal half of the 
shaft for biological fixation and is designed for a broach-
only technique.
The use of cementless femoral stems in THA was origi-
nally developed due to the high revision rates associated 
with poor cementing techniques [6]. Today’s cement-
ing techniques and corresponding implants have largely 
improved; however, the difference in revision rates between 
cemented and cementless fixation is minor and the topic of 
many debates. Cementless fixation has its own benefits and 
disadvantages. A major concern with this type of fixation is 
bone resorption secondary to the stress-shielding effects of 
the cementless stem. This concern has led to the on-going 
developments to improved femoral stem designs such as the 
 MasterSL, which aims to reduce stress shielding on the corti-
cal bone of the proximal femur. Furthermore, the redesigned 
 MasterSL femoral stem is proclaimed to have increased sta-
bility within the femoral canal. These advancements have 
been proposed to improve and prolong the lifespan of the 
THA implants.
In this single-centre prospective study, two experienced 
surgeons (KH and MW) assessed the  MasterSL femoral 
stem, which was new to the Australian market, and yet to 
have product registration at the commencement of the study 
period. The purpose of this study was to analyse the short-
term survivorship, clinical and radiological outcomes and 
patient-reported outcomes in 50 consecutive patients who 
underwent a THA with the new  MasterSL femoral stem, with 
a minimum 2-year follow-up.




For this single-centre prospective study, patients eligi-
ble for the study were provided with detailed informa-
tion regarding their involvement, and written consent was 
obtained prior to the study commencing.
Between February 2014 and October 2015, every patient 
presenting to the outpatient clinic of surgeons KH or MW 
with osteoarthritis of the hip as an indication for a THA 
was considered eligible for the study. Exclusion criteria 
included women who were pregnant, children and/or young 
people (i.e. < 18 years), people with an intellectual or mental 
impairment, people highly dependent on medical care and 
people in existing, dependent or unequal relationships with 
any member of the research team. Sixty-seven consecutive 
potential participants were screened and 17 were excluded. 
From the eligible cohort, 50 consecutive patients were ini-
tially recruited; however, an early dropout due to insurance 
issues necessitated a further recruit. A total of 50 hips (out 
of 49 patients) were included in the final analysis.
The surgeries were performed by two experienced sur-
geons (KH and MW) at the same hospital. Neither of the two 
surgeons had used the  MasterSL femoral stem before. Both 
surgeons were familiarised with the implant on a cadaver 
workshop provided by the company (LIMA). In addition, 
the surgeons operated together on three consecutive patients 
not included in the study, to gain more experience with the 
implant before the commencement of the study. Thereaf-
ter, each surgeon operated independently from the other 25 
THA study cases. The posterior approach (Moore) [7] was 
used for all patients, and the surgical technique was as per 
the technique guide provided by LIMA Corporate, which 
utilises traditional instrumentation [8]. The preparation of 
the proximal femur after resection of the femoral head and 
neck included following steps, which were identical for both 
senior surgeons: with the box-osteotome, an entry to the 
femoral canal was created by removing some medial por-
tions of the greater trochanter. The central canal reamer was 
used to determine the direction of the femur and with the 
curve rasp lateral cancellous bone was taken away. Sequen-
tial broaching was performed with a pneumatic broaching 
system until cortical fit medial and laterally was achieved.
The following pre- and post-operative patient-reported 
outcome measures (PROMs) were collected: The Harris Hip 
Score (HHS) [9] is a 100-point scale used to evaluate hip 
joint function, range of motion (ROM), pain and presence of 
deformities following THA; the Forgotten Joint Score (FJS) 
[10] asks the patient 12 questions regarding their awareness 
of their THA in everyday situations with a score ranging 
from 0 to 100 points; and the Oxford Hip Score (OHS) [11, 
12] evaluates hip pain in everyday situations and the ability 
to do basic functional tasks with scores ranging from 0 to 48.
Follow-up was performed at the 6-week, 6-month, 1-year, 
and 2-year mark. It included clinical and radiological assess-
ment and the completion of PROMs by the patient: HHS, 
OHS and FJS. The follow-up radiological images of the 
patients’ were assessed in regard to fixation (osteointegra-
tion) and stability using the Engh score [13] and analysed for 
subsidence and alignment. This was performed by another 
orthopaedic surgeon (CED), who was not part of the sur-
gical team and was blinded to the clinical outcome of the 
patients. The Engh grading scale is the most prominent scale 
reported in the literature, a measurement scale that was first 
published in 1989 [13]. It contains two subscales, fixation 
and stability, which are summed for a total score. Based 
on the total score, the implant is classified into one of four 
categories: “unstable” (< − 10), “suboptimum but stable” 
(− 10 to < 0), “ingrowth suspected” (0 to + 10) and “bone 
ingrown” (> + 10) [14]. In regard to fixation, the X-ray is 
examined for lines, lucencies, and spot welds. The criteria 
for stability are the appearance of smooth interfaces, the 
presence of pedestal, calcar modelling, interface deteriora-
tion, migration and particle shedding.
The measure of central tendency and dispersion for all 
data was reported as mean ± standard deviation, or as fre-
quencies for categorical data. Statistical analysis was per-
formed with IBM SPSS ver.23.0 software. The alpha level 
was set at 0.05 for level of statistical significance. A paired 
t test was used to compare pre- (pre-op) and post-operative 
(2-years post-op) PROMs. To determine the magnitude 
of differences measures between time points, effect size 
(Cohen’s d) was also calculated with interpretation of < 0.5, 
0.5–0.79 and > 0.8 considered as small, moderate and large, 
respectively.
Patient demographics (Table 1)
A total of 50 hips (out of 49 patients) were included in 
the final analysis: 20 female and 29 male patients with a 
mean age at time of surgery of 64.7 ± 10.5 years (range 
41–84 years), a body mass index (BMI) of 29.6 ± 5 (range 
21–41) and a subjective assessment of the overall health of 
the patient with the score of the American Society of Anes-
thesiologists (ASA) of 2.1 ± 0.49 (range 1–3). All but one 
patient’s primary diagnosis for THA was idiopathic osteo-
arthritis; one patient (bilateral THA) had secondary arthritis 
due to Perthes disease.
Implants
All THAs were performed with the same  MasterSL femoral 
stem (LIMA Corporate, Italy), in size and offset appropri-
ate to the patient’s anatomy. The femoral stems utilised 
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ranged from size 1 to size 12, with 42% (n = 21) receiv-
ing a lateralised stem. As such, almost the entire size 
range offered by the  MasterSL system was utilised in the 
course of this study (Fig. 2). Femoral heads were either 
cobalt–chromium–molybdenum (CoCrMo) metal (36%, 
n = 18) or  Biolox®delta ceramic (64%, n = 32). As the 
acetabular component, the Delta Primary System (LIMA 
Corporate, Italy) was utilised, with a trabecular titanium 
Delta-TT cup and either cross-linked polyethylene (60%, 
n = 30) or ceramic liners (40%, n = 20). For patients under 
60 and with high functional demand, a ceramic head was 
combined with a ceramic or polyethylene liner.
Results
Functional and radiological outcomes (Fig. 3 
and Table 2)
After the exclusion of one patient due to acute deep infec-
tion, two more patients were lost to follow-up. Therefore, 
a total of 46 patients (n = 47 hips) completed all assess-
ments at the 2-year mark. Pre-operative HHS compared to 
at 2-year follow-up improved significantly from 50.3 ± 17.4 
to 95.3 ± 5.8 (p < 0.001), and the mean OHS increased sig-
nificantly from 22.4 ± 7.5 to 46.1 ± 3.6 (p < 0.001), respec-
tively. The final HHS translates to 83% excellent, 13% good 
and about 4% fair results. Similarly, the OHS showed more 
Table 1  Patients demographics
OA osteoarthritis, BMI body mass index, ASA American society of 
anesthesiologist
*Values are expressed as mean ± standard deviation, with range in 
parentheses
Variable Value






 Secondary OA to Perthes 2
BMI (kg/m2)* 29.6 ± 5.0 (21–41)
ASA score (points) 2.1
Fig. 2  Frequency of femoral stem sizes used
Fig. 3  Mean PROMs at 6-week, 6-month, 12-month, and 2-year fol-
low-up for FJS, HHS and OHS
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than 91% excellent and about 9% good results. To detect any 
underlying bias of the investigator collecting the HHS, we 
compared the score improvements between the HHS and the 
OHS. No significant difference was seen (p = 0.215). The 
2-year FJS reports a mean of 86.4 ± 18.7 with 36% (n = 17) 
of patients reporting the highest score of 100 points and 
two-thirds above 85 points.
The follow-up radiological assessment showed a mean 
Engh score of +15.1 ± 5.9, ranging from +1 to +27. 43 out 
of 47 hips had an Engh score higher than 5. The alignment 
of the prosthesis was neutral (± 3°) in 44, varus (range: 
3–5.18°) in 3 and none were in valgus out of 47 hips. In 
regard to Engh’s assessment of subsidence, only one stem 
marginally breached the threshold of 2 mm when comparing 
the 6-week and 2-year follow-up X-rays. The mean subsid-
ence measurement was negligible being 0.5 mm ± 0.8 mm 
(range: − 0.9–2.2  mm). One other femoral stem had a 
suspected change of alignment between the 6-week and 
6-month X-rays from slight varus to neutral but with no 
signs of subsidence or any other signs of instability at the 
2-year follow-up.
As part of the Engh score, we observed on the 2-year 
post-operative X-rays that the majority of the femoral stems 
had some lucency lines surrounding the smooth distal part of 
the stem. This is not unusual for stems with good metaphy-
seal fixation. Some other patients (n = 7) showed diaphyseal 
cortex thickening with more pronounced stress shielding 
proximally, suggestive of distal fixation of the stem in the 
diaphysis (Fig. 4). However, this subgroup of patients did not 
show statistically significant differences for FJS (p = 0.62), 
HHS (p = 0.85) and Oxford (p = 0.31) as the p values are 
well above 0.05. As for effect size, they came out as 0.26 
(− 0.51–1.01) for FJS, 0.12 (− 0.64–0.88) for HHS and 0.54 
(− 0.24–1.30) for Oxford. So, there were only small differ-
ences for FJS and HHS as they were below 0.5, although 
the difference in Oxford was moderate as it was above 0.5.
Survivorship and complications
The aseptic survivorship of the  MasterSL femoral stem after 
2 years was 100%. Taking infections into consideration, we 
had one hip that failed and had to be revised. The complete 
implant of this joint had to be explanted due to deep infec-
tion (see below). No mechanical failure or aseptic loosening 
of any femoral stem was detected.
In this study, we had a total of five adverse events 
(Table 3), with one leading to the exclusion of the patient 
from the study. This patient had an acute deep infection 
4  weeks post-implantation and required revision sur-
gery with explantation of all implants and their compo-
nents. Therefore, the patient was removed from the study. 
Another patient had a non-displaced longitudinal hairline 
fracture distal to the stem. The fracture was identified on 
the 6-week post-operative X-rays and was treated con-
servatively by partial weight bearing for 4 weeks. A com-
puted tomography (CT) scan at 6 weeks post-operatively 
showed unchanged position of the stem with no evidence 
of subsidence and showed satisfactory callus formation. 
Table 2  Functional outcome 
and radiological results
PROM patient-reported outcome measures, HHS harris hip score, OHS Oxford hip score, FJS forgotten 
joint score
*Values are expressed as mean ± standard deviation, with range in parentheses
Variable Value
Pre-OP 2-year follow-up
PROMs (n = 47)
 HHS* 50.3 ± 17.4 (2–87) 95.3 ± 5.8 (78–100)
 HHS improvement* 45.1 ± 17.5 (7–86)
 OHS* 22.4 ± 7.5 (7–38) 46.1 ± 3.6 (30–48)
 OHS improvement* 23.7 ± 7.7 (10–39)
 FJS* 86.4 ± 18.7 (20.8–100)
Radiological assessment (n = 47)
Engh score* 15.1 ± 5.9 (1–27)
Alignment* 0.43° varus (2.49° valgus—4.69° varus)
 Neutral (± 3°) 44
 Varus (> 3°) 3
 Valgus (> 3°) 0
Subsidence
 Mean* 0.5 mm ± 0.8 (− 0.9–2.2)
  > 2 mm 1
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At 2-year follow-up, the fracture line was not visible on 
the X-ray and no subsidence was noted. The third patient 
developed a pulmonary embolism after surgery, which was 
confirmed on computed tomography of pulmonary arteries 
(CTPA). The patient was treated medically and recovered 
fully. The fourth patient had a fall on the ward on day 1 
post-operatively sustaining a traumatic dislocation of his 
operated hip. An immediate relocation of the hip under 
anaesthesia was performed and the patient had no further 
events or complications. The last patient initially had an 
uneventful surgery but developed persisting pain and signs 
of loosening around the acetabular component 15 months 
post-implantation, resulting in revision of the acetabular 
cup. During the revision surgery, there was no sign of 
infection and only the acetabular cup was exchanged. The 
femoral stem was noted to be in the correct position with-
out any signs of loosening and remained unchanged. Intra-
operative samples were taken and processed for microbiol-
ogy, and an infection was ruled out as cause of loosening 
of the acetabular component.
Discussion
Cementless fixation of the femoral stem in THA has shown 
great success especially in younger patients and is pre-
ferred by many experienced orthopaedic surgeons [15]. 
This type of fixation relies on good primary (mechani-
cal) and secondary (biological) integration. Manufactur-
ers address these important factors with specific THA 
implant design including materials, surface coatings and 
finishes. This study clinically investigated a redesigned 
femoral stem for THA, which was new to the Australian 
market and a refinement of a previously approved implant. 
THA is a successful and reliable treatment option for hip 
osteoarthritis with a vast variety of implants available on 
the market from multiple manufacturers. The Australian 
Joint Registry monitors the survivorship and revision rates 
for all THAs implanted in the country. Implants new to 
the market have to show their safety, longevity and survi-
vorship over the years because surgeons will refrain from 
using implants that have higher than average revision rates.
Fig. 4  Diaphyseal thickening in 7 out of 47 cases. Example of a 69-year-old male patient with BMI of 25.7 kg/m2. Follow-up X-rays: a pre-OP, 
b 6 weeks, c 1 year, d 4 years
Table 3  Summary of 
complications
Complication Number Remark
Acute deep infection 1 Exclusion from the study
Intraoperative periprosthetic hairline fracture 1 Conservative treatment, no sub-
sidence or loosening noticed
Pulmonary embolism 1 Conservative medical treatment
Early traumatic dislocation 1 On day 1, no further dislocations
Aseptic loosening of acetabular cup 1 Revision of cup, stem stable
a b C d 
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This study shows the first early results of the new 
 MasterSL femoral stem. The one major complication in 
this study, an acute deep infection, is unlikely to be related 
to the implant. The undisplaced hairline fracture identified 
in one patient is a complication seen occasionally with 
cementless femoral stems [15]. The surgeons in this study 
relate this complication to surgeon error rather than the 
implant itself.
The patients in this cohort have reported above average 
results in the HHS and OHS compared to the previously 
published literature [16–18]. In this study, excellent and 
good results in over 97% and 95% of patients were reported 
by the HHS and OHS, respectively, and fair was the worst 
score seen in this cohort.
The follow-up X-rays showed very good alignment of the 
femoral stem and a good fit in the metaphyseal and dia-
physeal regions. Consistently, the surgeons were able to 
place the stem in the most desirable neutral position. The 
use of the Engh score to evaluate the fixation and stabil-
ity of a cementless implant is of high value. Engh [13] 
was able to show that patients with scores above 5 were 
asymptomatic and had definite radiographic signs of bone 
ingrowth. Patients with positive scores between 0 and 5 had 
equally good clinical results but fewer radiographic signs of 
ingrowth [13]. In our study, all Engh scores were positive 
and more than 93% of patients had a score above 5.
Further evidence for good fixation is that no significant 
subsidence was measured on standard X-rays. Although 
X-ray measurements alone have limited accuracy, in con-
junction with the positive Engh scores and good PROM 
results, it is suggested that all femoral stems had a high 
level of biological fixation. As part of the Engh score, we 
observed on the 2-year post-operative X-rays that the major-
ity of the femoral stems had some lucency lines surrounding 
the smooth distal part of the stem. This is common for stems 
with good metaphyseal fixation. As mentioned in the results, 
seven patients showed diaphyseal cortex thickening which 
suggest distal fixation of the stem in the diaphysis (Fig. 4). 
The analysis of this subgroup and comparing it to all the 
other patients did not show any significant difference in their 
PROMs. Similar good results have also been seen with other 
tapered stems [19].
The short period of only 2-year follow-up is one limi-
tation of this study. Generally, long-term survivorship of 
an implant and its performance requires 10–15 years of 
registry data. Therefore, further research with a longer 
period of investigation is required to establish implant sur-
vivorship and its potential functional benefits. Secondly, 
for assessment of fixation only serial X-rays were available 
which are less sensitive for assessment than CT or bone 
scan. However, considering the PROMs and clinical exam-
ination did not suggest any signs of loosening, and this 
study had only positive Engh scores, these more in-depth 
imaging modalities which are more costly and come with 
more radiation exposure would have not been justifiable.
The success of this new femoral stem in terms of survi-
vorship and revision rates can only be properly evaluated 
with a larger cohort and longer-term data. The Australian 
joint registry will be a good tool to monitor the perfor-
mance of this implant. In this small and limited study, the 
results are promising and show that the  MasterSL femoral 
stem achieves similar short-term results to the best-per-
forming implants available.
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